neuropacs, which is developing AI-driven neurological diagnostic software, announced it has raised more than $1 million in seed financing to expand product development and prepare for broader clinical commercialization.
The company said the funding followed a private investor event held earlier last year at the office of Richard A. Staab, a philanthropist and figure in neurological and health-tech circles. In the wake of that meeting, investors organized Neuro Investment Group, LLC under Staab’s leadership, with the group making an initial investment alongside additional backing from other supporters of neuropacs’ technology.
Neuropacs said it will use the proceeds to accelerate technology development, add key hires, and pursue strategic partnerships as it works toward wider clinical adoption.
The company’s flagship software is an automated MRI processing and machine learning platform designed to help clinicians diagnose and differentiate common neurodegenerative forms of parkinsonism, including Parkinson’s disease, multiple system atrophy (parkinsonian variant), and progressive supranuclear palsy. Neuropacs said the test relies on a single, non-invasive diffusion MRI scan without radiotracers, can be performed on 3 Tesla scanners from major vendors, and applies a free-water imaging model paired with a machine learning algorithm to provide results indicating the likely presence of PD, MSA, or PSP.
Neuro Investment Group said it was formed to back diagnostics and neurological care technologies that can improve diagnostic accuracy, patient outcomes, and care efficiency, with an emphasis on companies it believes have a clear pathway to broad clinical adoption.
KEY QUOTES:
“This funding marks a significant milestone for neuropacs. It not only fuels our next phase of innovation, but also validates our mission to revolutionize diagnostics in neurology. We’re deeply grateful to our early investors who believe in the transformative potential of our work.”
Dr. Martin Handfield, President and CEO, neuropacs
“Neuropacs is addressing a critical unmet need in neurodegenerative diseases with a rigorously validated, clinically practical AI platform. From our first discussions, it was clear that the team combines deep scientific expertise with a disciplined vision for commercialization. We believe this new technology will be very impactful in healthcare.”
Richard A. Staab, Managing Partner, Neuro Investment Group
